ストックスクリーナーアプリを入手
44.27
2.14%
-0.97
アフターアワーズ：
44.27
前日終値:
$45.24
開ける：
$45.27
24時間の取引高:
653.78K
Relative Volume:
1.32
時価総額：
$2.16B
収益：
$307.03M
当期純損益:
$-99.81M
株価収益率:
-21.39
EPS:
-2.0695
ネットキャッシュフロー:
$-27.20M
1週間 パフォーマンス:
+1.33%
1か月 パフォーマンス:
+6.75%
6か月 パフォーマンス:
+5.40%
1年 パフォーマンス:
+71.39%
1日の値動き範囲:
$44.20
$46.78
1週間の範囲:
$40.00
$47.43
52週間の値動き範囲:
$23.83
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
44.27 | 2.16B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Stock Titan
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Canada
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Revenue $111.6M, vs. FactSet Est of $98.4M - marketscreener.com
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q1 Loss $0.30 Per Share, vs. FactSet Est of $-0.31 - marketscreener.com
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
Learn to Evaluate (MIRM) using the Charts - news.stocktradersdaily.com
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - DutchNews.nl
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd. - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts - Defense World
Leerink Partnrs Issues Negative Outlook for MIRM Earnings - The AM Reporter
Research Analysts Offer Predictions for MIRM Q1 Earnings - Defense World
Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - NewsBreak: Local News & Alerts
Mirum gets FDA nod for tablet version of liver drug, Livmarli - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Mirum Pharmaceuticals Inc [MIRM] stock was sold by Howe Jolanda at the price of US$0.11 million - knoxdaily.com
KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Corebridge Financial Inc. - Defense World
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Teacher Retirement System of Texas - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
MIRM Stock Sees Decline of Approximately -3.74% in Last Five Days - knoxdaily.com
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
LIVMARLI Now Approved In Japan For ALGS And PFIC - MarketScreener
LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire
First-Ever Treatment for ALGS and PFIC Approved in Japan: LIVMARLI Makes History - Stock Titan
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):